引導式測驗 · 中等 等級
EMA與藥品監管中的AI測驗
測試 EMA 反思文件狀態、生命週期範圍、特定功能證據、監督以及與產品授權的差異。
問題 1 的 8
哪一項陳述描述了EMA AI反思文件的狀態?
預覽每個問題8 問題
當您參加測驗時,就會出現答案和解釋。
- 哪一項陳述描述了EMA AI反思文件的狀態?
- It describes regulatory considerations but is not an AI product authorization
- It grants automatic approval to AI tools
- It replaces medicines legislation
- It is a standalone CE certificate
- Which stages of medicines work may involve AI?
- Only clinical diagnosis
- Only hospital billing
- Research, development, manufacturing, and medicine use
- Only marketing
- What should developers define before evaluating an AI function?
- The total number of data records
- Its intended purpose, context, users, and consequences of error
- Only its neural-network architecture
- The vendor’s product slogan
- Why does human oversight matter for higher-impact uses?
- It guarantees that the model is accurate
- It replaces data validation
- It makes change control unnecessary
- Qualified review and escalation help manage uncertain or erroneous outputs
- Which controls should accompany changes to an AI model over time?
- Versioning, change management, monitoring, and traceability
- Nothing if the model remains AI
- A new medicine approval for every typo
- A single performance report from development
- Does the reflection paper create one universal AI approval pathway?
- Yes, one pathway applies to every algorithm
- Yes, if the tool is used for medicine
- No AI use can be regulated
- No; existing requirements depend on the function and product
- How should clinical trial AI be documented?
- No details if the trial is blinded
- With data provenance, protocol alignment, validation, and limitations
- Only a vendor name
- Only the output score
- 贊助方在部署AI於歐盟醫藥工作前應諮詢什麼?
- A general AI product blog
- A prior model card regardless of use
- Current EMA and applicable EU guidance and legislation
- Only the reflection paper in isolation